Progression of bicuspid-related aortopathy in patients undergoing transcatheter aortic valve implantation: Rationale and design of the international, multicenter PROSPERO-TAVI registry.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Costa Giuliano, Laterra Giulia, Sammartino Sofia, De Backer Ole, Jia Yuheng, Pilgrim Thomas, Daijiro Tomii, Montorfano Matteo, Ancona Francesco, Bellini Barbara, Redwood Simon, Patterson Tiffany, Kornowski Ran, Hamdan Ashraf, Mylotte Darren, Del Sole Paolo Alberto, Saia Francesco, Palmierini Tullio, Bedogni Francesco, Gandolfo Caterina, Cannata Stefano, Garot Philippe, Gall Emmanuel, De Carlo Marco, Angelillis Marco, Immè Sebastiano, Tamburino Corrado, Mangieri Antonio, Tartaglia Francesco, Nombela Luis, Santos Ignacio Amat, Gomez Mario Garcia, Attizzani Guilherme, Frazzetto Marco, Calì Mariachiara, Millar Kevin, Webb John, Barbanti Marco
Аннотация
METHODS: The progression of bicuspid-related aortopathy in patients undergoing Transcatheter Aortic Valve Implantation (PROSPERO) registry is an investigator-initiated, multicenter, observational, ambi-spective registry designed to evaluate the aortopathy progression in consecutive BAV patients undergoing TAVI.
RESULTS: All patients with native bicuspid aortic valve who underwent TAVI for severe aortic stenosis between January 2018 and December 2019 with available preprocedural computed tomography angiography (CTA) assessment are considered. The primary endpoint of the study is to assess the progression of BAV-associated aortopathy at follow-up. Secondary endpoints include long-term clinical outcomes and aortopathy-related events.
CONCLUSIONS: The PROSPERO registry will provide real-world evidence on the evolution of BAV-associated aortopathy after TAVI. Its results may help define follow-up strategies and improve patient selection and management in this increasingly relevant population.
TRIAL REGISTRATION: ClinicalTrials.govNCT06248294.